Sandra Cortez-Maya

Dr. Sandra Cortez-Maya


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2017 in Nanomaterials
Verified
Journal Article
Open access
PDF file
LPLuis Daniel Pedro
Luis Daniel Pedro
EMElena Martínez-Klimova
Elena Martínez-Klimova
SCSandra Cortez-Maya
Sandra Cortez-Maya
SMSonia Mendoza-Cardozo
Sonia Mendoza-Cardozo
TRTeresa Ramírez-Ápan
Teresa Ramírez-Ápan
MMMarcos Martínez-García
Marcos Martínez-García
Ibuprofen has been reported to possess anticancer activity. In the present work, four ibuprofen conjugates of resorcinarene-Polyamidoamine PAMAM-dendrimers were synthesized with eight or 16 ibuprofen moieties. The ibuprofen was released from the dendrimers in a dependent manner. The drug-conjugated nanoresorcinarene-dendrimers showed higher cellular uptake than free ibuprofen. In vitro cytotoxicity studies were performed with free ibuprofen and with the synthesized conjugates in U251, PC-3, K-562, HCT-15, MCF-7, SKLU-1, and MDA U251 (human glioblastoma), PC-3 (human prostatic adenocarcinoma), K-562 (human chronic myelogenous leukemia cells), HCT-15 (human colorectal adenocarcinoma), MCF-7 (human mammary adenocarcinoma), SKLU-1 (human lung adenocarcinoma), and MDA-MB-231 (human mammary adenocarcinoma) cancer cell lines by different cytotoxicity assays. Ibuprofen conjugates of the first and second generations showed significant cytotoxic effects towards the human glioblastoma (U251) and human mammary adenocarcinoma (MCF-7, MDA) cell lines. Moreover, the ibuprofen conjugates improved cytotoxicity compared to free ibuprofen. Increased therapeutic efficacy was observed with specific ibuprofen conjugates of the second generation using low doses.

1 January 2012 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
SCSandra Cortez-Maya
Sandra Cortez-Maya
SHSimón Hernández-Ortega
Simón Hernández-Ortega
TRTeresa Ramírez-Apan
Teresa Ramírez-Apan
ILIrina V. Lijanova
Irina V. Lijanova
MMMarcos Martínez-García
Marcos Martínez-García

1 March 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
AMAntonio Moreno-Herrera
Antonio Moreno-Herrera
SCSandra Cortez-Maya
Sandra Cortez-Maya
VBVirgilio Bocanegra‐García
Virgilio Bocanegra‐García
BBBimal Banik
Bimal Banik
Gildardo RiveraGildardo Rivera
Gildardo Rivera
Infections caused by Trypanosoma brucei, Trypanosoma cruzi, Leishmania spp., Entamoeba histolytica, Giardia lamblia, Plasmodium spp., and Trichomonas vaginalis, are part of a large list of human parasitic diseases. Together, they cause more than 500 million infections per year. These protozoa parasites affect both low- and high-income countries and their pharmacological treatments are limited. Therefore, new and more effective drugs in preclinical development could improve overall therapy for parasitic infections even when their mechanisms of action are unknown. In this review, a number of heterocyclic compounds (diamidine, guanidine, quinoline, benzimidazole, thiazole, diazanaphthalene, and their derivatives) reported as antiprotozoal agents are discussed as options for developing new pharmacological treatments for parasitic diseases.

14 September 2011 in Synthetic Communications
Verified
Journal Article
Closed access
SCSandra Cortez-Maya
Sandra Cortez-Maya
ECE. Cortes Cortes
E. Cortes Cortes
SHSimón Hernández-Ortega
Simón Hernández-Ortega
TAT. Ramirez Apan
T. Ramirez Apan
MMMarcos Martínez-García
Marcos Martínez-García
A number of 2-aminobenzophenones have been synthesized by acylation of para-chloroaniline with different 2-, 3-, 4-chloro- or fluorobenzoyl chloride in solid state via the Friedel–Crafts reaction. Synthesized compounds were characterized by 1H and 13C NMR, Fourier transform–infrared, ultraviolet–visible spectroscopy, mass spectrometry, and elemental analysis. Evaluation of biological activity in vitro showed that the selected compounds 9, 10, and 13 have potential anticancer activity. The presence of one chlorine atom in the second aromatic ring of the benzophenone molecule makes it more active.

25 September 2020 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
SCSandra Cortez-Maya
Sandra Cortez-Maya
AMAntonio Moreno-Herrera
Antonio Moreno-Herrera
IPIsidro Palos
Isidro Palos
Gildardo RiveraGildardo Rivera
Gildardo Rivera
Parasitic diseases, caused by helminths (ascariasis, hookworm, trichinosis, and schistosomiasis) and protozoa (chagas, leishmaniasis, and amebiasis), are considered a serious public health problem in developing countries. Additionally, there is a limited arsenal of anti-parasitic drugs in the current pipeline and growing drug resistance. Therefore, there is a clear need for the discovery and development of new compounds that can compete and replace these drugs that have been controlling parasitic infections over the last decades. However, this approach is highly resource- intensive, expensive and time-consuming. Accordingly, a drug repositioning strategy of the existing drugs or drug-like molecules with known pharmacokinetics and safety profiles is alternatively being used as a fast approach towards the identification of new treatments. The artemisinins, mefloquine, tribendimidine, oxantel pamoate and doxycycline for the treatment of helminths, and posaconazole and hydroxymethylnitrofurazone for the treatment of protozoa are promising candidates. Therefore, traditional antiprotozoal drugs, which were developed in some cases decades ago, are a valid solution. Herein, we review the current status of traditional anti-helminthic and antiprotozoal drugs in terms of drug targets, mode of action, doses, adverse effects, and parasite resistance to define their suitability for repurposing strategies. Current antiparasitic drugs are not only still viable for the treatment of helminth and protozoan infections but are also important candidates for new pharmacological treatments.

13 August 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
SCSandra Cortez-Maya
Sandra Cortez-Maya
LPLuis Daniel Pedro
Luis Daniel Pedro
EMElena Martínez-Klimova
Elena Martínez-Klimova
TRTeresa Ramírez-Ápan
Teresa Ramírez-Ápan
MMMarcos Martínez-García
Marcos Martínez-García
Improving the activity and selectivity profile of anticancer agents will require designing drug carrier systems that employ soluble macromolecules. Olsalazine-PAMAM-dendrimer-salicylic acid-conjugates with dendritic arms of different lengths have shown good stability regarding the chemical link between drug and spacer. In this study, the drug release was followed in vitro by ultraviolet (UV) studies. Evaluation of the cytotoxicity of the olsalazine-PAMAM-dendrimer-salicylic acid-conjugates employing a sulforhodamine B (SRB) assay in PC-3 (human prostatic adenocarcinoma) and MCF-7 (human mammary adenocarcinoma) cell lines demonstrated that conjugate 9 was more active as an antiproliferative agent than cisplatin, and no cytotoxicity towards the African green monkey kidney fibroblast (COS-7) cell line was observed in any of the conjugates synthesized in the present work.